Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 3Plasma cell 2Thoracic 1Sarcoma 1NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × cabozantinib × Endocrine × Clear all
NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
49 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡